An Intelligent DNA Nanorobot with in Vitro Enhanced Protein Lysosomal Degradation of HER2

• Published in: Nano letters Vol. 19; no. 7; pp. 4505 - 4517
• Main Authors: Ma, Wenjuan, Zhan, Yuxi, Zhang, Yuxin, Shao, Xiaoru, Xie, Xueping, Mao, Chenchen, Cui, Weitong, Li, Qian, Shi, Jiye, Li, Jiang, Fan, Chunhai, Lin, Yunfeng
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 10.07.2019
• Subjects: Animals; Aptamers, Nucleotide - chemistry; Aptamers, Nucleotide - pharmacology; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; DNA - chemistry; DNA - pharmacology; Drug Delivery Systems; Endocytosis - drug effects; Female; Humans; Lysosomes - metabolism; Lysosomes - pathology; MCF-7 Cells; Mice; Mice, Nude; Proteolysis - drug effects; Receptor, ErbB-2 - metabolism; Robotics; Xenograft Model Antitumor Assays; breast cancer; DNA nanorobot; HER2; framework nucleic acids; aptamer; lysosome
• DOI: 10.1021/acs.nanolett.9b01320
• ISSN: 1530-6984; 1530-6992

DNA nanorobots have emerged as new tools for nanomedicine with the potential to ameliorate the delivery and anticancer efficacy of various drugs. DNA nanostructures have been considered one of the most promising nanocarriers. In the present study, we report a DNA framework-based intelligent DNA nanorobot for selective lysosomal degradation of tumor-specific proteins on cancer cells. We site-specifically anchored an anti-HER2 aptamer (HApt) on a tetrahedral framework nucleic acid (tFNA). This DNA nanorobot (HApt-tFNA) could target HER2-positive breast cancer cells and specifically induce the lysosomal degradation of the membrane protein HER2. An injection of the DNA nanorobot into a mouse model revealed that the presence of tFNA enhanced the stability and prolonged the blood circulation time of HApt, and HApt-tFNA could therefore drive HER2 into lysosomal degradation with a higher efficiency. The formation of the HER2-HApt-tFNA complexes resulted in the HER2-mediated endocytosis and digestion in lysosomes, which effectively reduced the amount of HER2 on the cell surfaces. An increased HER2 digestion through HApt-tFNA further induced cell apoptosis and arrested cell growth. Hence, this novel DNA nanorobot sheds new light on targeted protein degradation for precision breast cancer therapy.